On the 28th and 29th of last month, at the 'Nature Conference: Engineered Models of Human Disease' held in Serbia, Professor Seungwoo Cho, CEO of Ceragen and a professor in the Department of Biotechnology at Yonsei University, participated as an invited speaker.

Professor Cho introduced Ceragen's core technology, the ECM (Extracellular Matrix)-based organoid platform, under the theme 'Engineering organoids for advanced disease models.'

This conference, hosted by the world-renowned scientific journal Nature, is an international academic event where researchers worldwide share their research achievements on the engineering reproduction of human diseases. Professor Cho was the only Korean selected among the 12 invited speakers from around the world.

The ECM-based organoids he presented are evaluated as a technology that can enhance the precision of disease modeling and improve the efficiency of new drug development by implementing an environment similar to actual human tissue. This technology is particularly gaining attention as a next-generation alternative amid growing interest in animal replacement testing methods. ECM is emerging as a key element that can overcome the limitations of existing cultivation techniques by providing a microenvironment that can precisely control cell growth and differentiation.

Based on this ECM technology, Ceragen is expanding its application range by launching the beauty and medical aesthetics brand 'Cellume.' This brand, which combines organoid and biomaterial technology, is exploring various possibilities, including skin regeneration.

Popular News